Management of Sleep Disorders and Mental Focus

Introduction to Sleep Disorder Management

The American Academy of Sleep Medicine recommends starting with Cognitive Behavioral Therapy for Insomnia (CBT-I) as first-line treatment for nighttime sleep, then adding low-dose doxepin or suvorexant if needed, with moderate-quality evidence supporting these interventions 1, 2, 3
CBT-I demonstrates superior long-term outcomes with moderate-quality evidence showing improvements in sleep onset latency, wake after sleep onset, sleep efficiency, and sleep quality across multiple delivery formats (in-person, telephone, web-based, self-help books) 1, 2, 4

The American Academy of Sleep Medicine suggests zolpidem 10 mg (5 mg in elderly) for sleep onset difficulty, with moderate-quality evidence for improving sleep onset latency and total sleep time 1, 2, 3
Ramelteon 8 mg is suggested for sleep onset insomnia with a favorable safety profile 3
Low-dose doxepin (3-6 mg) is the preferred option for sleep maintenance difficulty, with low-to-moderate quality evidence showing improvement in total sleep time and wake after sleep onset, particularly favorable in older adults 1, 2, 4, 3, 6
Suvorexant has moderate-quality evidence for reducing wake after sleep onset by 16-28 minutes through orexin receptor antagonism 1, 2, 3
Eszopiclone 2-3 mg has low-to-moderate quality evidence for both sleep onset and maintenance 1, 2, 3

The American Academy of Sleep Medicine does not recommend over-the-counter antihistamines (diphenhydramine) due to lack of efficacy data and risks of daytime sedation, delirium, and anticholinergic effects, especially in older adults 3, 6
Trazodone is specifically not recommended by the American Academy of Sleep Medicine despite widespread off-label use 3
Benzodiazepines (lorazepam, temazepam) should not be first-line due to dependence risk, falls, cognitive impairment, and withdrawal reactions 3, 6

Implement CBT-I first through any available format (individual, group, web-based, self-help), with moderate-quality evidence supporting its effectiveness 1, 2, 3
Identify the primary sleep complaint and consider patient-specific factors, such as age and history of substance abuse, when selecting pharmacological options 3
Use the lowest effective dose for the shortest duration, typically less than 4 weeks for acute insomnia, and reassess regularly every 2-4 weeks during active treatment 3

All hypnotics carry significant risks, including complex sleep behaviors (sleep-driving, sleep-walking), daytime impairment, falls, fractures, and cognitive impairment, particularly in elderly patients 3
Never combine multiple sedative medications, as this significantly increases risks of complex sleep behaviors, cognitive impairment, falls, and fractures 3
Benzodiazepines have black box warnings and should be avoided in older adults and those with cognitive impairment 3, 6